◀ Back to MAPK3
MAPK3 — PRKAB1
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Li et al., Circ Res 2005
(Myocardial Ischemia) :
In isolated heart muscles, the
AMPK activator 5-aminoimidazole-4-carboxy-amide-1-beta-D-ribofuranoside ( AICAR )
increased p38
MAPK activation ... p38
MAPK recruitment to TAB1/AMPK complexes
required AMPK activation and was reduced in ischemic AMPK-deficient transgenic mouse hearts
Capano et al., Biochem J 2006
(Myocardial Ischemia) :
Inhibition of p38
MAPK with SB203580
attenuated the phosphorylation of the downstream substrates, MAPK activated protein kinases 2 and 3, but not that of the upstream MAPK kinase 3, nor of
AMPK
Cheng et al., Biochim Biophys Acta 2006
:
Inhibition of
AMPK reduces p38
MAPK phosphorylation, suggesting that AMPK lies upstream of p38 MAPK
Li et al., Endocrinology 2007
:
We conclude that in cultured bAECs, TNF-alpha induces insulin resistance in the phosphatidylinositol 3-kinase/Akt/eNOS pathway via a p38
MAPK dependent mechanism and enhances ERK1/2 and
AMPK phosphorylation independent of the p38 MAPK pathway
Ho et al., Biochem Biophys Res Commun 2007
:
In conclusion, increasing
AMPK activity by AICAR and AMPKgamma1 mutation does not
increase p38
MAPK phosphorylation in skeletal muscle
Jacquet et al., Cardiovasc Res 2007
(Disease Models, Animal...) :
Finally, pharmacological inhibition of
AMPK during ischemia with compound C did not
attenuate the coincident activation of p38
MAPK
Hu et al., Hepatology 2008
(Carcinoma, Hepatocellular...) :
Furthermore, CNTF induced
mitogen activated protein kinase ( MAPK ) activation
suppresses AMPK activity in the early phase of CNTF stimulation
Han et al., J Cell Physiol 2009
:
AICAR was able to activate p38 MAPK and pre-treatment with AMPK inhibitor or expression of
KD-AMPK blocked this p38
MAPK activation
Liu et al., Cell cycle (Georgetown, Tex.) 2009
(Breast Neoplasms) :
At the molecular level, metformin increases
P-AMPK ,
reduces P-EGFR, EGFR,
P-MAPK , P-Src, cyclin D1 and cyclin E ( but not cyclin A or B, p27 or p21 ), and induces PARP cleavage in a dose- and time dependent manner
Kim et al., J Biol Chem 2011
(MAP Kinase Signaling System) :
Expression of dominant negative
AMPK suppressed HCSA mediated phosphorylation of p38
MAPK , and inhibition of AMPK and p38 MAPK blocked HCSA induced glucose uptake
Jo et al., Nat Prod Res 2012
:
Inhibition of
AMPK activity
reduced p38 MAPK phosphorylation, whereas the inhibition of p38
MAPK activity did not affect AMPK phosphorylation
Damm et al., Mol Endocrinol 2012
(MAP Kinase Signaling System) :
Inhibitory effects of a-MSH on
AMPK were
blocked by specific inhibitors of protein kinase A (PKA) or
ERK-1/2 , pointing to an important role of both kinases in this process
Shen et al., J Biomed Biotechnol 2012
:
Nuclear NT-PGC-1a can be increased by activation of protein kinase A.
Activation of p38
MAPK by muscle activity or of
AMPK had no effect on the subcellular distribution of NT-PGC-1a
Arsikin et al., Biochim Biophys Acta 2012
(Neuroblastoma) :
6-OHDA induced phosphorylation of p38
mitogen activated protein ( MAP ) kinase in an
AMPK dependent manner, and pharmacological inhibition of p38 MAP kinase reduced neurotoxicity, but not AMPK activation and autophagy triggered by 6-OHDA
Choi et al., J Cell Physiol 2013
(Neoplasms) :
Furthermore, whereas Compound C ( an
AMPK inhibitor ), AMPK-DN ( AMPK-dominant negative ) mutant, and SB203580 ( a p38
MAPK inhibitor ) did not block the 8-Cl-cAMP induced phosphorylation of Akt/PKB, TCN ( an Akt1/2/3 specific inhibitor ) and an Akt2/PKBß targeted siRNA inhibited the 8-Cl-cAMP- and AICAR mediated phosphorylation of AMPK and p38 MAPK
Paweł et al., Lipids 2013
(Leiomyoma...) :
Additionally, in uterine leiomyomas we found relevant activation of both PTEN and
MAPK(ERK1/2) signaling pathways with only a minor change in AKT activity and relatively absent
HIF-1a/AMPK activation